# US 8,540,983 B2 · Debriding composition from bromelain and methods of production thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,540,983 B2
- Document ID: US8540983B2
- Status: Granted
- Kind: B2
- Application number: 13/366,954
- Filed: 2012-02-06
- Published: 2012-07-05
- Granted: 2013-09-24
- Earliest claimed: 2004-11-22
- Assignees: MediWound Ltd.
- Applicants: Marian Gorecki; Amir Toren
- Inventors: Marian Gorecki; Amir Toren
- Web page: https://patentgrep.com/patent/US8540983B2

## CPC

- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61K 38/4873: {Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H}
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a debriding composition obtained from bromelain and to methods of producing same. Particularly, the present invention relates to a debriding composition obtained from bromelain comprising proteolytic enzymes having molecular weights of about 23 kDa, being essentially devoid of bromelain inhibitors, and to pharmaceutical compositions comprising same. The debriding compositions and the pharmaceutical compositions comprising same are particularly useful in debriding eschar tissues and in wound healing.

## Claims

### Claim 1

A debriding composition obtained from bromelain, the debriding composition comprising a plurality of different proteolytic enzymes having molecular weights of about 23 kDa as determined by size exclusion chromatography, wherein the plurality of different proteolytic enzymes comprises:
(a) stem bromelain comprising SEQ ID. No. 1;
(b) ananain comprising SEQ ID No. 2;
(c) stem bromelain comprising SEQ ID No. 3; and
(d) cysteine proteinase precursor comprising SEQ ID No. 4, said debriding composition comprising bromelain inhibitors in an amount of less than 10% w/w of protein content of the debriding composition, wherein the composition consists essentially of a single protein peak after elution from an HPLC size exclusion column TSK-Gel 3000SWXL, the single protein peak constituting proteins having molecular weights of about 23 kDa.

### Claim 2 (depends on 1)

The debriding composition according to claim 1 further comprising a pharmaceutically acceptable carrier.

### Claim 3 (depends on 1)

A method of treating a wound by debriding non-viable tissues comprising applying a therapeutically effective amount of the debriding composition according to claim 1 to a wound.

### Claim 4 (depends on 3)

The method of treating a wound according to claim 3, wherein the debriding composition further comprises a pharmaceutically acceptable carrier.

### Claim 5 (depends on 3)

The method of treating a wound according to claim 3, wherein the wound is selected from the group consisting of full and partial thickness burn wounds, sunburns, frostbite, ulcerative lesions, pressure ulcers, varicose ulcers, stasis ulcers, trophic ulcers, wounds associated with surgical procedures, amputation, incision, circumcision and episiotomy, traumatic and pyogenic wounds, vaginitis, cervicitis, pilonidal cyst wounds, cataract scar tissue, and skin graft sites.